Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Harvard Business School
Fuji
Cipla
Healthtrust
Fish and Richardson
Argus Health
Farmers Insurance
UBS

Generated: November 17, 2018

DrugPatentWatch Database Preview

Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant - Biologic Drug Details

« Back to Dashboard

Summary for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
Tradenames:1
Patents:5
Applicants:1
BLAs:1
Suppliers: see list1

US Patents for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Merck Sharp & Dohme Corp. GARDASIL human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant INJECTION, SUSPENSION 125126 001 2006-06-08 ➤ Try a Free Trial Chevron Phillips Chemical Company LP (The Woodlands, TX) ➤ Try a Free Trial search
Merck Sharp & Dohme Corp. GARDASIL human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant INJECTION, SUSPENSION 125126 001 2006-06-08 ➤ Try a Free Trial SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) ➤ Try a Free Trial search
Merck Sharp & Dohme Corp. GARDASIL human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant INJECTION, SUSPENSION 125126 001 2006-06-08 ➤ Try a Free Trial SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) ➤ Try a Free Trial search
Merck Sharp & Dohme Corp. GARDASIL human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant INJECTION, SUSPENSION 125126 001 2006-06-08 ➤ Try a Free Trial ALDERBIO HOLDINGS LLC (Las Vegas, NV) ➤ Try a Free Trial search
Merck Sharp & Dohme Corp. GARDASIL human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant INJECTION, SUSPENSION 125126 001 2006-06-08 ➤ Try a Free Trial Progenra, Inc. (Malvern, PA) The Children\'s Hospital of Philadelphia (Philadelphia, PA) ➤ Try a Free Trial search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant

Supplementary Protection Certificates for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00043 Denmark ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
C0024 France ➤ Try a Free Trial PRODUCT NAME: NATALIZUMAB,ANTICORPS MONOCLONAL HUMANISE ANTI-INTEGRINE ALPHA-4; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
C/GB02/026 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ANAKINRA (ALSO KNOWN AS HUMAN IL-1RA); REGISTERED: UK EU/1/02/203/001 20020308; UK EU/1/02/203/002 20020308; UK EU/1/02/203/003 20020308; UK EU/1/02/203/004 20020308
2016 00031 Denmark ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
C/GB94/014 United Kingdom ➤ Try a Free Trial PRODUCT NAME: RECOMBINANT HUMAN FACTOR- VIII (BHK); REGISTERED: NL 16789 19940419; NL 16790 19940419; NL 16791 19940419; UK 0010/0194 19940517; UK 0010/0195 19940517; UK 0010/0196 19940517
2015000061 Germany ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Covington
Cipla
AstraZeneca
Cantor Fitzgerald
Express Scripts
Chinese Patent Office
Deloitte
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.